Stage II HR-Positive Invasive Lobular Carcinoma: Tanya's Patient Story

Patient Info: Tanya, Female, 40s | Stage II

Biomarkers: Genetic testing negative; Oncotype DX score 27; MammaPrint low risk; ER-positive

Tanya had Stage II ER-positive breast cancer with a large lobular tumor found on MRI, underwent bilateral mastectomy with immediate reconstruction, completed 4 rounds of chemotherapy, and started tamoxifen.

Lobular Breast Cancer AllianceRead more →

Stage II Invasive Ductal Carcinoma: Roxanne's Survivor Story

Patient Info: Roxanne, Female, Under 40 | Stage II

Biomarkers: Genetic testing reported no hereditary/family-risk finding; tumor biomarker status not reported

Completed chemotherapy, surgery, and radiation for Stage IIB invasive ductal carcinoma; the source title identifies no evidence of disease after treatment, and she described herself as a survivor after finishing treatment on 28 April 2025.

breastcancer.orgRead more →

Stage II BRCA2 Breast Cancer: Rachel's Patient Story

Patient Info: Rachel Zitofsky, Female, Under 40 | Stage II

Biomarkers: BRCA2 mutation

Rachel was doing well 4.5 years after Stage II breast cancer diagnosis and continued tamoxifen; her BRCA2 result also led her sister to expanded testing and preventive care.

Memorial Sloan KetteringRead more →

Stage II HR-Positive Invasive Lobular Carcinoma: Eutha's Survivor Story

Patient Info: Eutha, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

Eutha completed clinical-trial immunotherapy, right mastectomy with lymph-node removal, chemotherapy, radiation and reconstruction for Stage II ER-positive, PR-positive, HER2-positive breast cancer, and returned to work and community life; no explicit NED/cancer-free status was provided.

Memorial Sloan KetteringRead more →

Stage II Breast Cancer: Nicole's Survivor Story

Patient Info: Nicole Grogan, Female, 40s | Stage II

Nicole completed surgery, chemotherapy, radiation and the exercise trial, and had no evidence of disease at her July 2019 appointment.

Memorial Sloan KetteringRead more →

Stage II Invasive Ductal Carcinoma: Dwan's Survivor Story

Patient Info: Dwan Thomas, Female | Stage II

Biomarkers: HER2-negative; estrogen-positive

Dwan completed treatment for Stage II HER2-negative, estrogen-positive invasive ductal carcinoma in 2017 and later became active in MD Anderson advocacy and fundraising efforts.

MD AndersonRead more →

Stage II Invasive Lobular Carcinoma: Jane's Patient Story

Patient Info: Jane, Female, 50s | Stage II

Nearly 3 years into her breast-cancer journey, she was continuing long-term hormone therapy and active patient advocacy.

Lobular Breast Cancer AllianceRead more →

Stage II Breast Cancer: Naomi's Patient Story

Patient Info: Naomi Arbel-Brodd, Female | Stage II

Twenty years after her 2006 diagnosis, she had returned to UT MD Anderson as a weekly volunteer supporting other women receiving breast cancer care.

MD AndersonRead more →

HER2-Positive Breast Cancer Treatment Followed by Multiple Myeloma

Patient Info: Anonymized, female, 50s | Stage II

Biomarkers: ER-negative; PR-negative; HER2 3+; Ki-67 70%

Postoperative imaging showed no breast cancer recurrence or distant metastasis, and the breast cancer was described as stable when a separate multiple myeloma diagnosis was made.

PubMed CentralRead more →

Breast cancer treatment changed after severe colitis

Patient Info: Anonymized, Female, 50s | Stage II

Biomarkers: HER2-positive, ER-negative, PR-negative

In April 2025, follow-up evaluation showed no evidence of breast cancer recurrence.

PubMed CentralRead more →

Stage II Breast Cancer: Renée's Survivor Story

Patient Info: Renée, Female, Under 40 | Stage II

Renée described her health as stable and her treatment as working. She remained on a long-term hormone-based anti-cancer regimen and was still healing from reconstruction complications rather than describing herself as cancer-free.

The Patient StoryRead more →

Stage II Triple-Negative Breast Cancer: Lucy's Survivor Story

Patient Info: Lucy, Female, Under 40 | Stage II

Biomarkers: Germline BRCA1 mutation; triple-negative breast cancer

Surgical pathology was all clear on June 17 after a strong chemotherapy response. Lucy described herself as cancer-free and continued oncology reviews every 3–4 months while planning delayed reconstruction.

The Patient StoryRead more →

Stage II Triple-Negative Breast Cancer: Melissa's Survivor Story

Patient Info: Melissa, Female | Stage II

Biomarkers: Triple-negative breast cancer; BRCA testing negative; NBN gene mutation identified on later testing

Melissa completed pregnancy-adapted cancer treatment, later underwent risk-reducing surgery and reconstruction, and was raising both daughters.

The Patient StoryRead more →

Stage II Breast Cancer: Wendi's Survivor Story

Patient Info: Wendi Kushner | Stage II

Biomarkers: Triple-positive

After the clinical trial, lumpectomy pathology showed a complete pathological response with no residual cancer in the breast or lymph nodes.

MD AndersonRead more →

Stage IIA triple-negative neuroendocrine breast carcinoma with chemoimmunotherapy response

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Triple-negative neuroendocrine breast carcinoma with PD-L1 CPS >=10, and reported germline BRCA1/2 mutation.

As of March 2025, 12 months after surgery, follow-up imaging and tumor-marker testing showed no local recurrence or distant metastasis, and she remained in good general condition.

PubMed CentralRead more →

Stage II Invasive Ductal Carcinoma: Margaret's Survivor Story

Patient Info: Margaret, Female | Stage II

Biomarkers: Onco-typing score 18; hormone-responsive tumor described; exact receptor status not reported

As of June 2026, Margaret’s story described completed surgery, chemotherapy, radiation, and later reconstruction for Stage II IDC/DCIS breast cancer, with survivorship focused on recovery, neuropathy, and integrative support rather than an explicit NED claim.

The Patient StoryRead more →

Stage II Invasive Ductal Carcinoma: Monica's Survivor Story

Patient Info: Monica, Female, Under 40 | Stage II

As of June 2026, Monica described survivorship after treatment for Stage IIB breast cancer and a separate undifferentiated pleomorphic sarcoma, with lasting neuropathy, bone pain, reconstruction complications, and grief around fertility.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Cat's Survivor Story

Patient Info: Cat, Female | Stage II

Biomarkers: ER-positive; Oncotype recurrence risk discussed

As of June 2026, Cat described being cancer-free after bilateral mastectomy, 4 months of chemotherapy, reconstruction, and a period on tamoxifen for ER-positive Stage IIB breast cancer.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Bethany's Patient Story

Patient Info: Bethany W., Female, Under 40 | Stage II

Biomarkers: ER-positive; hormone-positive

As of June 2026, Bethany described care for late Stage II/early Stage III ER-positive breast cancer, beginning with AC chemotherapy and Taxol after scans showed no distant spread, with surgery, radiation, and hormone therapy planned as next phases.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Doreen's Patient Story

Patient Info: Doreen, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Doreen had completed TCHP chemotherapy with a complete response before surgery and had undergone lumpectomy and radiation for Stage IIA triple-positive breast cancer.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Callie's Survivor Story

Patient Info: Callie, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of June 2026, Callie described survivorship after mastectomy, ACT chemotherapy, reconstruction, and hysterectomy for Stage IIB ER-positive IDC, with all cancer-directed treatment completed by the end of 2019.

The Patient StoryRead more →

Stage II BRCA1 Breast Cancer: Joy's Survivor Story

Patient Info: Joy R., Female | Stage II

Biomarkers: BRCA1 mutation

As of June 2026, Joy had no evidence of disease after chemotherapy, double mastectomy, and hysterectomy for Stage II breast cancer with a BRCA1 mutation, and had moved from 3-month to 6-month oncology monitoring.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Rach's Patient Story

Patient Info: Rach D., Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Rach described Stage II triple-positive breast cancer treated with fertility preservation, 6 rounds of neoadjuvant TCHP including Herceptin, Zoladex ovarian suppression, and double mastectomy with reconstruction.

The Patient StoryRead more →

Stage II Breast Cancer: Jenna's Patient Story

Patient Info: Jenna, Female, Under 40 | Stage II

Biomarkers: Hormone receptor-positive; HER2-negative; BRCA inherited gene mutations negative

As of April 2026, Jenna had completed pregnancy-associated chemotherapy and double mastectomy for Stage II HR-positive, HER2-negative breast cancer with 1 involved lymph node, did not need radiation, and was on hormone therapy for 10 years.